+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effect of Topical Iganidipine on Experimental Elevation of Aqueous Flare Induced by Prostaglandin E 2 and EP Agonists in Pigmented Rabbits

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          We evaluated the role of topical iganidipine on experimental aqueous flare elevation in rabbits. Transcorneal diffusion of prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), 25 µg/ml or 7.09 × 10<sup>–2</sup> mmol/l, or highly selective agonists for prostaglandin E<sub>2</sub> receptor subtypes (EP), 25 µg/ml, was achieved with the use of a glass cylinder to produce aqueous flare elevation in pigmented rabbits. Iganidipine was topically administered before application of PGE<sub>2</sub> or EP agonists. Aqueous flare was measured with a laser flare cell meter. Topical instillation of 0.1% iganidipine once or twice inhibited 64 ± 8% (p < 0.01) and 84 ± 9% (p < 0.01) of PGE<sub>2</sub>-induced aqueous flare elevation, respectively. Two instillations of 0.1% iganidipine inhibited 95 ± 5% (p < 0.01) of EP2-agonist(ONO-AE1-259-01)-induced flare elevation and 98 ± 3% (p < 0.01) of EP4-agonist(ONO-AE1-392)-induced flare rise. Topical iganidipine may have anti-inflammatory activity in the eye.

          Related collections

          Author and article information

          Ophthalmic Res
          Ophthalmic Research
          S. Karger AG
          August 2002
          16 September 2002
          : 34
          : 4
          : 195-199
          Department of Ophthalmology, Toyama Medical and Pharmaceutical University, Toyama, Japan
          63876 Ophthalmic Res 2002;34:195–199
          © 2002 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 4, Tables: 3, References: 11, Pages: 5
          Original Paper


          Comment on this article